Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human, Phase 1 Dose Escalation and Dose Expansion Trial to Assess the Safety and Tolerability of COM503 as Monotherapy and in Combination Therapy in Participants With Advanced Solid Malignancies

NCT06759649 is registered in ClinicalTrials.gov with Compugen Ltd as lead sponsor.

NCT NCT06759649
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06759649 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human, Phase 1 Dose Escalation and Dose Expansion Trial to Assess the Safety and Tolerability of COM503 as Monotherapy and in Combination Therapy in Participants With Advanced Solid Malignancies
Lead sponsor
Compugen Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
January 7, 2025
Completion date
November 22, 2027
Enrollment
200 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, malignant tumors, neoplasm